Prof. Dr. Dr. h. c. Karl-Heinrich Link. Scientific Activities up to 12/2015

Transkript

1 Prof. Dr. Dr. h. c. Karl-Heinrich Link Scientific Activities up to 12/ Professional data/cv (p 1-6) - Scientific contributions (p 6-227) - Professional Data / CV (p 1-6) Prof. Dr. med. Dr. h.c. Karl-Heinrich Link Director Surgical Center and Asklepios Tumor Center Rhein/Main (ATC) Asklepios Paulinen Klinik (APK) Geisenheimer Str. 10 D Wiesbaden Germany Sekretaries: B. Grädigk G. Hoffmann Mail: k-h.link@asklepios.com Fax: www : cancer.de 1

2 Professional Development and Status School, Medical Training Study Medicine Justus-Liebig-Universität, Gießen 1978 Medical Exam Justus-Liebig-Universität Gießen 1978 Approbation Surgical Pathology, Justus-Liebig-Universität Gießen Prof. Dr. J. Kracht 1980 Dissertation and Doctoral Degree at Justus-Liebig-Universität Gießen Prof. Dr. Ch. Müller-Eckhardt Immungenetische und -serologische Untersuchungen zum Vorkommen des Antigens HLA-B12 auf menschlichen Thrombozyten DFG-Grant/Postdoctoral Training Professor Dr. Charles Heidelberger Dept. Basic Research at LAC/USC Cancer Center, Los Angeles/USA Carcinogenesis, 5-FU Development, Drug Testing Surgical Training Department General Surgery Justus-Liebig-Universität Gießen Director: Prof. Dr. K. Schwemmle 2

3 /01 Department General Surgery University Hospital Ulm Director: Prof. Dr. H.G. Beger 1989 Qualifying Exam "Surgeon" /01 Senior Surgeon Department General Surgery, University of Ulm 1994 Habilitation/Thesis at University of Ulm Chemosensitivity Testing for Optimization of Regional Chemotherapy of solid Tumors; Basic Research and Clinical Application 1994 Venia Legend 1995 Qualification as " Visceral Surgeon" Deputy Director and Management of Ulm Cancer Center 2001 Professor of Surgery, Univ. U /01 Director Surgical Oncology Department General- and Visceral Surgery, University Hospital Ulm /01 Deputy Director Department General- and Visceral Surgery, University Hospital Ulm /01 Head Senior Surgeon and Board of Directors Surgical Center, University Hospital Ulm Since 01/2002 Director Surgical Center and Asklepios Tumortreatment Center Rhein/Main (ATC) Asklepios Paulinen Klinik, Wiesbaden 2003 Doctor honoris causa Univ. Yangzhou, China 2012 Faculty Member Asklepios-Semmelweis Medical School Asklepios Campus Hamburg 3

4 Personalia Board of Directors, Co-Chairman, Visceral Surgical Group for Surgical Oncology, German Society of General/Visceral Surgery (CAO-V/DGAV) Board of Directors Colon- and Rectal Cancer Group CAO-V (-2015) Cofounder and President International Colon and Rectal Cancer Club (ICRCC) President, Board of Directors, Cancer Society Hessen (Hessische Krebsgesellschaft e. V. (- 07/2012) Board of Directors Cancer Society Baden-Württemberg ev. (-12/2001) Member German S3-Guide Line Committees Colon-and Rectal Cancer, Pancreatic Cancer, and Psychooncology Member Structural Commission for Bowel Cancer Centers, Visceral Cancer, and Oncological Centers, German Cancer Society Organization/Coorganization of many national/international meetings Guest surgeon at many international universities Visiting Professor, Guest Speaker at International Universities Chairman Bowel Cancer Center APK Wiesbaden (Certified by DKG) Chairman Center for the Treatment of Malignant Peritoneal Diseases (Certified by DGAV) Memberships European Society of Surgical Oncology (ESSO) German Society of Surgery (DGCH) German Society of General and Visceral Surgery (DGAV) German Cancer Society (DKG) Konvent Leading Hospital Surgeons (KLK) Visceral Surgical Society for Oncology (CAO-V) CAO-V Group Peritoneal Disease CAO-V Group Colon and Rectal Cancer International Colorectal Cancer Club (ICRCC) Cancer Society Hessen Other Memberships (In part contemporary) Member Charles Heidelberger Group und des Charles Heidelberger Award Committee: J.S. Bertram (Honolulu,USA), P.V. Danenberg (Los Angeles, USA), E. Huberman (Argonne, USA), P. Jones (Los Angeles, USA), (Ulm), E. Mihich (Buffalo, USA), J. Kubota (Yokohama, Japan), T. Kuroki (Tokyo, Japan). International Advisory Board of International Conferences on Anti-Cancer Treatment (ICACT, Paris, Universities Paris/SOMPS and MD Anderson Cancer Centers) Member of the International Scientific Advisory Community. 4th International Conference of the Asian Clinical Oncology Society (ACOS) 1999 Honorary member Chilenian Society of Surgery Krementz Award Committee, ICRCT 91/93/95/97 4

5 Contemporary Member Consensus Conference Multimodal Treatment of Colon and Rectal Cancer Board Member of Milan Consensus Conference on Peritoneal Carcinosis Treatment Programs 2007 Editorial Boards "Langenbeck s Archives of Surgery", "Clinical Colorectal Cancer", Gastrointestinal Surgery", "Onkologie (contemp.)", Visceral Medicine. Abstract Reviewer s Board of the yearly German Surgical Society (DGCH and DGAV) Meetings Speaker Medical Board Surgery Asklepios (more than 150 Hospitals; ) Major Achievements 1. Clinically: Prolongation of survival and cure rates in patients with colon-, rectal, and pancreatic cancer. Introduction of multimodal therapy in colon- and rectal cancer in Germany. Downstaging and curative resection of primarily nonresectable liver tumors (one of the first three groups worldwide). Improvement of response and survival by individualizing chemotherapy using PCR techniques and cell cultures (first worldwide). First to report split liver resection with treatment individualization. Foundation and leadership of the national intersdisciplinary working group "Forschungsgruppe Onkologie Gastrointestinale Tumoren (FOGT)"; conduction of the 2 largest German phase III trials on multimodal therapy in colon and rectal cancer. Conduction of phase III trials involving treatment individualization/molecular prognostic factors (among the groups worldwide). Major contributions to "Quality control in colon and rectal cancer surgery". 2. Professionally: Nationally and internationally active and recognized as Surgical Oncologist and Visceral Surgeon. Among the top ranking in DKG benchmarking of large bowel cancer centers. More than 140 chairmanships; memberships in organizing and selection committees in national/international Scientific Meetings. Organization of workshops and regular international meetings (BIC) on colorectal and pancreatic surgery. 3. Communication: Organisation of national- and international meetings with participation of most renowned clinical and basic researchers in their fields: Colon- and Rectal Cancer, Pancreatic Cancer, Gastrointestinal Cancers, Liver Tumors and other visceral diseases. 5

6 4. Publications: More than 300 publications, numerous in nationally/internationally journals of highest impact (Ann Surg, Arch Surg, Lancet, Cancer Research, Clinical Cancer Research, Cancer, Langenbeck s Arch Surg, World J Surgery, Eur J Surg Oncol, Chirurg, etc.). Edition/Coedition of 5 Books. 5. Presentations: More than 1000 presentations, many of them in highly recognized national/international meetings; numerous review talks on Oncologic or Visceral Surgical Topics. 6. Surgery: More than 8000 visceral surgical procedures. Surgical training with one of the nationally and internationally most renowned pancreatic/visceral surgeon (Prof. Dr. H. G. Beger). 7. Recommended Member Focusliste (German List of Excellence in Oncological Treatment) for Surgery of Colon- and Rectal Cancer, Pancreatic Cancer, and Metastases. Team rated as among the best according to benchmarking of DKG German Large Bowel Cancer Centers. 8. Management: Cancer Center, University Hospital-Surgical Department and Center; Surgical Center and ATC at APK in Wiesbaden, Large Bowel Cancer Center ATC Wiesbaden/DKG, and Center for Malignant Diseases of the Peritoneum/DGAV - Scientific contributions /2015 (p 6-227) I. Papers (p 7-33) - Most relevant publications - List of all publications II. Book articles, Book editions, Published abstracts (p 34-57) III. Oral presentations (p ) 6

7 First author - Coauthor (excerpts according to specialties/topics) - First author - Coauthor (all oral presentations according to specialties/topics) Posters IV. Chairmanships (p ) V. Congress organizations (p ) VI. Awards (p ) VII. International Workv (p ) I. Papers (p 7-33) Most relevant publications First author 1986 K. H. Link et al. Prospective correlative chemosensitivity testing in high dose intraarterial chemotherapy for liver metastases Cancer Research 46, K. H. Link et al. Concentration and time dependance of the toxicity offluorinated pyrimidines to HT29 colorectal carcinoma cells Cancer Chemotherapy and Pharmacology 22, K. H. Link et al. Rationales for intraperitoneal chemotherapy. Chemosensitivity Testing and Pharmacokinetic Considerations - Clinical Experience with Intraperitoneal Chemotherapy. Acta Chirurgica Austriaca 27,

8 1996 K. H. Link et al. Regional Chemotherapy Directed by Individual Chemosensitivity Testing in Vitro: A Prospective Decision-Aiding Trial Clinical Cancer Research 3, K. H.Link et al. Multimodal Therapies in Ductal Pancreatic Cancer Int. J. Pancreatol. 21, K. H. Link et al. Downstaging by regional chemotherapy of non resetable isolated colorectal liver metastases Eur J Surg Oncol 25, K. H. Link et al. Thymidilate synthase quantitation and in vitro chemosensitivity testing predicts responses and survival of patients with isolated non-resectable liver tumors receiving hepatic arterial infusion Cancer 89, Note. Honoured by Cancer als "Best Paper of the Year 2000" 2000 K. H. Link et al. Neue Prinzipien in der Chirurgischen Onkologie. Onkologe 6, K. H. Link et al. Surgery, Radio- and Chemotherapy for Multimodal Treatment of Rectal Cancer Swiss Surg 7, K. H. Link et al. Regional Chemotherapy of Nonresectable Colorectal Liver Metastases with Mitoxantrone, 5-Fluorouracil, Folinic Acid, and Mitomycin C May Prolong Survival Cancer 92, K.H. Link Wandel der Therapie beim resektablen Rektumkarzinom. Internist 42, K. H. Link et al. 8

9 Chirurgie und multimodale Therapie des Kolonkarzinoms: Evidenzbasis? Chir Gastroenterologie 20, K. H. Link et al. Multimodality Treatment of Hepatic Metastases. In: Lencioni et al., Springer, K. H. Link et al. Increase of Survival Benefit in Advanced Resectable Colon Cancer by Extent of Adjuvant Treatment Annals of Surgery 242, K. H. Link et al.: Colon cancer: survival after curative surgery Langenbeck s Arch Surg 390, , M. Hauser, M. Mann, P. M. Schlag Kolonkarzinom -Chirurgische Onkologie Strategien und Standards für die Praxis Michael Gnant, Peter M. Schlag (Hrsg.) Springer, K. H. Link et al. Multimodale Therapie von Kolon- und Rektumkarzinomen Qualitätsparameter Viszeralmedizin 25, K. H. Link et al. Qualitätsanforderungen zur Behandlung des Kolon- und Rektumkarzinoms aus chirurgischer Sicht Chirurg 81, K. H. Link, H.Hauser, M.Mann, P.M.Schlag Kolonkarzinom - Die Sicht der Chirurgie. Wiener Klinisches Magazin 14, 3, Co- and senior (last) author 1997 H. G. Beger, M. H.Schoenberg, K. H. Link, F. Safi, D. Berger Die Duodenum erhaltende Pankreaskopfresektion - Ein Standardverfahren bei chronischer Pankreatitis 9

10 Chirurg 68, H. G. Beger, F. Gansauge, M. W. Büchler, K. H.Link Intraarterial adjuvant chemotherapy after pancreaticoduodenectomy for pancreatic cancer significant reduction of occurence of liver metastasis World J Surg 23, JP Neoptolemos, JA Dunn, DD Stocken, J Almond, KH Link, H. Beger, C Bassi, M Falconi, P Pederzoli, C Dervenis, L Fernandez-Cruz, F Lacaine, A Pap, D Spooner, DJ Kerr, H Friess, MW Büchler for the European Study Group for Pancreatic Cancer: Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomized controlled trial The Lancet 358, L Staib, KH Link, A Blatz, H.G Beger: Surgery of Colorectal Cancer: Surgical Morbidity and Five- and Ten-year Results in 2400 Patients Monoinstitutional Experience World J Surg 26, M Kornmann, KH Link: Conversion of locally inoperable primary rectal cancer with multiple liver metastases to an option for cure after local down-staging and hepatic arterial infusion chemotherapy. Langenbeck s Arch Surg 387, BUM Monz, HH König, R Leidl, L Staib, K.H.Link: Cost Effectiveness of Adding Folinic Acid to Fluorouracil Plus Levamisole as Adjuvant Chemotherapy in Patients with Colon Cancer in Germany. Pharmacoeconomics 21, M Kornmann, W Schwabe, S Sander, M Kron, J Strater, S Polat, E Kettner, HF Weiser, W Baumann, H Schramm, P Hausler, K Ott, D Behnke, L Staib, H.G Beger, K.H.Link Thymidylate Synthase and dihydropyrimidine dehydrogenase mrna expression levels predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil. Clin Cancer Research 9, H.G Beger, B Rau, F Gansauge, B Poch, KH Link 10

11 Treatment of Pancreatic Cancer. Challenge of the Facts. Editorial Update World J Surg 27, M Kornmann, L Staib, KH Link Aktuelle chirurgische Therapiestrategien - Rektumkarzinom Verdauungskrankheiten 25, Th Weber, KH Link Radikale Chirurgie bei primär metastasierten kolorektalen Karzinomen Chir Gastroenterol 23, W. Hohenberger,, J. Spatz, M. Anthuber, U.Widmaier, M.H. Schoenberg Stellenwert der laparoskopischen operativen Behandlung von Rektumkarzinomen Chirurgische Praxis 70, M. Kornmann, L.Staib, T.Wiegel,, E. D. Kreuser, M. Kron, W. Baumann, D. Henne-Bruns, and K. H. Link Adjuvant radiochemotherapy of advanced resectable rectal cancer: results of a randomised trial comparing modulation of 5-fluorouracil with folinic acid or with interferon alpha Br J Cancer 103, Th. Weber, M. Roitman, K. H. Link: Current Status of Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy in Patients With Peritoneal Carcinomatosis From Colorectal Cancer. Clinical Colorectal Cancer, Vol.11, Nr.3, List of all publications Original papers first author Original papers coauthor Book contributions first author Book contributions coauthor Book editions etc. 11

12 Published abstracts first author Published abstracts coauthor Casuistics/Case reports Original papers first author K. H. Link, M. Roitman, Th. Müller, F. Strobel, E. Bungert Notfälle in der Geriatrie aus viszeralchirurgischer Sicht. Neuro-Geriatrie 2, 71-72, 2013 K. H. Link, Therapie von Tumoren der Bauchspeicheldrüse bei VHL Betroffenen. VHL Rundbrief, 13, 4-7, 2012 K. H. Link, H. Hauser, M. Mann, P. M. Schlag. Kolonkarzinom. Die Sicht der Chirurgie. Wiener Klinisches Magazin 3, 18-24, Wiener Klinische Wochenschrift 11-12, 2011 K. H. Link, M. Kornmann, R. Bittner, F. Köckerling, R. Arbogast, I. Gastinger, W. Heitland, D. Henne- Bruns, H. Lang, H. Lippert, M. Mann, H. J. Meyer, M.-J. Polonius, S. Post, R. Raab, T. Schiedeck, V. Schumpelick Qualitätsanforderungen zur Behandlung des Kolon- und Rektumkarzinoms - Aus chirurgischer Sicht Chirurg 81, , 2010, M. Kornmann, M. Kornmann, R. Bittner Multimodale Therapie von Kolon- und Rektumkarzinomen: Qualitätsparameter Gastrointestinal Medicine and Surgery Viszeralmedizin 2009; 25:

13 , M. Roitman How to treat Peritoneal Metastases or Primary Tumors Proceedings/Abstract Book, 20th ICACT, MTP 16, , M. Roitman, M. Mann, B. Schneider, Th. Weber New Management in the Treatment of Colorectal Cancer Proceedings/Abstract Book, 19th ICACT, EL -9, 95-99, 2008, M. Kornmann, M. Mann, L. Staib Quality Control in Interdisciplinary Colon- and Rectal Cancer Treatment: Case Load or more? Proceedings/ Abstract Book 18th International Congress on Anti Cancer Treatment (ICACT) 2007, P. M. Schlag Exzessive Palliativchirurgie Chirurgische Gastroenterologie, 23, , 2007, T. Weber Radikale Chirurgie bei primär metastasierten kolorektalen Karzinomen Chirurgische Gastroenterologie, 23, , 2007 Diagnose und chirurgische Therapie von Bauchspeicheldrüsentumoren VHL-Rundbrief, Heft 3, Jahrgang 8, 5-9, 2007, L. Staib, W. Baumann, M. Redenbacher, S. Sander, D. Henne-Bruns, M. Kornmann Modulation of adjuvant 5-FU treatment by folinic acid and interferon-alpha in colon and rectal cancer: Comparison of two phase-iii trials including 1652 patients European Journal of Surgical Oncology (EJSO), Volume 32, Suppl.I, ,

14 , T.A. Sagban, M. Mann Surgery and Multimodal Therapy in Rectal Cancer Proceedings/Abstract Book 17th International Congress on Anti Cancer Treatment (ICACT) , 2006, M. Kornmann, L. Staib, M. Redenbacher, M. Kron, H.G. Beger Increase of Survival Benefit in Advanced Resectable Colon Cancer by Extent of Adjuvant Treatment: Results of a Randomized Trial Comparing Modulation of 5-FU + Levamisole with Folinic Acid or with Interferon-? Annals of Surgery, 2005, Volume 242, Number 2, , T.A. Sagban, Z.L. Ji Surgery and Multimodal Therapy in Colon and in Rectal cancer Journal of Clinical Medicine in Practice, 9, 2005, 9-27, T.A. Sagban, M. Moerschel, K. Tischbirek, M. Holtappels, V. Apell, K. Zayed, M. Kornmann, L. Staib Colon cancer: survival after curative surgery Langenbeck s Archives of Surgery, 390, 83-93, 2005, M. Mörschel, TA Sagban, V. Apell, M. Holtappels, K. Tischbirek Chirurgie und multimodale Therapie des Kolonkarzinoms: Evidenzbasis Chirurgische Gastroenterologie, 20 (1), 39-54, 2004, M. Roitman, M. Holtappels, I. Runnebaum, H. Urbanzyk, G. Leder, L. Staib Intraperitoneal chemotherapy with mitoxantrone in malignant ascites Surg Oncol Clin N Am, 12(3), ,

15 Laudatio zur Emeritierung von Herrn Prof. Beger, Univ Ulm Intern, 349, II/01, 2001, E. Sunelaitis, M. Kornmann, M. Schatz, F. Gansauge, G. Leder, A. Formentini, L. Staib, J. Pillasch, H-G. Beger Regional Chemotherapy of Nonresectabele Colorectal Liver Metastases with Mitoxanrone, 5- Fluorouracil, Folinic Acid, and Mitomycin C May Prolong Survival Cancer, 92, , 2001, G. Leder, A. Formentini, H.G. Beger Impact of celiac arteryinfusion chemotherapy (CAI) or CAI+Radiotherapy on tumor biology and survival in resected and locally advanced nonresectable pancreatic cancer Anticancer Research 21, , 2001 Wandel der Therapie bei resektablem Rektumkarzinom Der Internist, 42: , 2001, L. Staib, M. Kornmann, A. Formentini, M. Schatz, P. Suhr P. Messer, E. Röttinger, H.G. Beger Surgery, Radio- and Chemotherapy for Multimodal Treatment of Rectal Cancer Swiss Surgery 7, , 2001, G. Leder, A. Formentini, H.G. Beger Impact of celiac arteryinfusion chemotherapy (CAI) or CAI+Radiotherapy on tumor biology and survival in resected and locally advanced nonresectable pancreatic cancer Anticancer Research 21, , 2001, M. Kornmann, U. Butzer, G. Leder, E. Sunelaitis, J. Pillasch, D. Salonga, K.D. Danenberg, P.V. Danenberg, H-G. Beger Thymidylate Sythase Quantitation an In Vitro Chemosensitivity Testing Predicts Responses and 15

16 Survival of Patients with Isolated Nonresectable Liver Tumors Receiving Hepatic Arterial Infusion Chemotherapy Cancer, 89, Nr. 2, , 2000 K. H. Link, J. Pillasch, A. Formentini, E. Sunelaitis, G. Leder, F. Safi, M. Kornmann, H.G. Beger Downstaging by regional chemotherapy of nonresectable isolated colorectal liver metastases. European Journal of Surgical Oncology 25 (1999), K. H. Link, A. Formentini, G. Leder, G. Fortnagel, N. Warszawski, E. Papachristou, M.B. Lutz, M.H. Schoenberg, H.G. Beger Systemische und regionale Chemotherapie, Strahlentherapie und Kombinationsbehandlungen beim Pankreaskarzinom. Verdauungskrankheiten 16 (1998) K. H. Link, A. Formentini, G. Leder, G. Fortnagel, N. Sartori, M. Schatz, H.H. Beger Resection and Radiochemotherapy of Pancreatic Cancer - The Future? Langenbeck's Archives of Surgery 383 (1998) K. H. Link, L. Staib, M. Schatz, P. Suhr, E. Röttinger, H.G. Beger Rectal Cancer: Adjuvant radiochemotherapy - what is the patients benefit? Langenbeck's Archives of Surgery 383 (1998) K. H. Link, L. Staib, M. Schatz, P. Suhr, E. Röttinger, H.G. Beger Multimodal therapy in rectal cancer. Japanese Journal of Cancer and Chemotherapy 25 (14) (1998) K. H. Link, G. Leder, J. Pillasch, U. Butzer, L. Staib, M. Kornmann, U. Brückner, H.G. Beger In vitro concentration response studies and in vitro phase II tests as the experimental basis for regional chemotherapeutic protocols. 16

17 Seminars in Surgical Oncology 14 (1998) K. H. Link, L. Staib, H. Bernhart, E.D. Kreuser, P. Suhr, E. Röttinger, H.G. Beger Acceptance and toxicity of postoperative adjuvant therapy in colon and rectal cancers. Interim Report on the Trials FOGT 1 and FOGT 2 of the German Forschungsgruppe Onkologie Gastrointestinaler Tumoren (FOGT). Onkologie 20 (1997) K. H. Link, F. Gansauge, J. Görich, G. H. Leder, N. Rilinger, H.G. Beger Palliative and adjuvant regional chemotherapy in pancreatic cancer. Eur.J.Surg.Oncol.23 (1997) K. H. Link, F. Gansauge, N. Rilinger, H.G. Beger Celiac Artery Adjuvant Chemotherapy. Int. J. Pancreatol 21 (1997) K. H. Link, F. Gansauge, J. Pillasch, H.G. Beger Multimodal Therapies in Ductal Pancreatic Cancer. Int. J. Pancreatol. 21 (1997) K. H. Link, A. Formentini, F. Gansauge, E. Papachristou, H.G. Beger Regional celiac artery infusion as adjuvant treatment after pancreatic cancer resection. Digestion 58 (1997), K. H. Link, F. Gansauge, M. H. Schoenberg, L. Staib, A. Formentini G. Fortnagel, N. Warszawski, M.B. Lutz, Th. Gress, H. G. Beger Palliative, adjuvante Therapieoptionen beim Pankreaskarzinom unter Berücksichtigung der regionalen Chemotherapiemöglichkeiten. Acta Chir. Austriaca 29 (1997)

18 K. H. Link, L. Staib, E.-D. Kreuser, H.G. Beger Adjuvant Treatment of Colon and Rectal Cancer: Impact of Chemotherapy, Radiotherapy, and Immunotherapy on Routine Postsurgical Patient Management. Recent Results Cancer Research 142 (1996) K. H. Link, M. Kornmann, G. Leder, U. Butzer, J. Pillasch, L. Staib, F. Gansauge, H.G.Beger Regional Chemotherapy Directed by Individual Chemosensitivity Testing in Vitro: A Prospective Decision-aiding Trial. Clinical Cancer Research 3 (1996) K. H. Link, G. Hepp, L. Staib, U. Butzer, W. Böhm, H.G. Beger Intraperitoneal regional chemotherapy with mitoxantrone. Cancer Treatment and Research 81 (1996) K. H. Link, U. Butzer, J. Pillasch, G. Hepp, H.G. Beger In vitro pharmalogic rationale for intraperitoneal regional chemotherapy. Cancer Treatment and Research 82 (1996) K. H. Link, M. Kornmann, H.-J. Lenz, U. Butzer, J. Pillasch, F. Safi, F. Gansauge, K. D. Danenberg, P.V. Danenberg, H. G. Beger Response prediction in hepatic artery infusion with fluoropyrimidines using cell culture and thymidylate synthase quantitation. Reg. Cancer Treat. 8 (1995) K. H. Link, G. Hepp, U. Butzer, L. Staib, R. Kunz, J. Pillasch, F. Gansauge, Ch. Schaller, H.G. Beger Rationales for Intraperitoneal Chemotherapy: Chemosensitivity Testing and Pharmacokinetic Considerations - Clinical Experience with Intraperitoneal Chemotherapy. Acta Chir. Austriaca 27 (1995)

19 K.H.Link Chemosensitivitätsuntersuchungen zur Optimierung der Regionalen Chemotherapie solider Tumoren. Grundlagen und Klinische Applikation. Habilitationsschrift, Fakultät für Klinische Medizin, Universität Ulm (1994) K. H. Link, F. Gansauge, J. Pillasch, N. Rilinger, M. Büchler, H.G. Beger Regional Treatment of Advanced Nonresectable and of Resected Pancreatic Cancer via Celiac Axis Infusion. (First Results of a Single Institution Study) Dig Surg 11 (1994) K. H. Link, K.R. Aigner, J. Pillasch, J. Ullrich, F. Gansauge and D.H. Kern Individual Chemosensitivity Testing for Regional Chemotherapy in a Prospective Correlative and a Prospective Decision Aiding Test. Reg Cancer Treat 3 (1993) K. H. Link, E.D. Kreuser, F. Safi, J. Ullrich, A. Schalhorn, E. Schmoll, H.G. Beger Die intraarterielle Chemotherapie mit 5-FU und Folinsäure (FA, Rescuvolin) im Therapiekonzept bei nicht resektablen kolorektalen Lebermetastasen. Ein Vergleich von 5-FU/FA i.a. vs. 5-FU/FA i.v. vs. 5-FUDR i.a. oder 5-FUDR i.a.+i.v. Tumor Diagnostik und Therapie 14 (1993) K. H. Link, H.G. Beger Was ist gesichert in der Chemo- und Immuntherapie solider Tumoren. Standardprotokolle, Studien und neue Entwicklungen. Chirurg 63 (1992) K. H. Link, M. Büchler Levamisol und Fluorouracil zur adjuvanten Therapie des resezierten Kolonkarzinoms? Arzneimitteltherapie 4 (1992)

20 K. H. Link, G. Hepp, L. Staib, R. Kunz, U. Butzer, W. Böhm, H.G. Beger Intraperitoneale regionale Chemotherapie (IPRC) mit Mitoxantron. Grundlagen und Klinik. Aktuelle Onkologie 66 (1992) K. H. Link In vitro Interaktion von Mezlocillin mit 5-Fluorouracil und mit Mitomycin C. Arzneimittelforschung/Drug Research 39 (II), 11 (1989) K. H. Link, L. Staib, H.G. Beger Influence of exposure concentration and exposure time (cxt) on toxicity of cytostatic drugs to HT29 human colorectal carcinoma cells. Characterization of drugs for (regional) chemotherapy. Regional Cancer Treatment 2 (1989) K. H. Link, K.R. Aigner, D. Kessler In vitro chemosensitivity profiles of human malignancies for high dose regional chemotherapy. Contributions to Oncology 29 (1988) K. H. Link, K.R. Aigner, K. Peschau, M. Warthona, K. Schwemmle, P.V. Danenberg Concentration and time dependence of the toxicity of fluorinated pyrimidines to HT29 colorectal carcinoma cells. Cancer Chemotherapy and Pharmacology 22 (1988) K. H. Link, K.R. Aigner, W. Kuehn, K. Schwemmle, D.H. Kern Prospective correlative chemosensitivity testing in high-dose intraarterial chemotherapy for liver metastases. Cancer Research 46 (1986) K. H. Link, K.R. Aigner, W. Kühn, N. Roetering, K. Schwemmle Chemosensitivitätsbestimmung in vitro bei regionaler Chemotherapie von Lebertumoren. 20

21 Tumor Diagnostik & Therapie 6 (1985) K. H. Link, K.R. Aigner, W. Kühn, N. Rötering Zytostatikasensitivitätstestung perioperativ und im Tumorzell-Kolonien-Test (TKT) in vitro bei hochdosierter intraarterieller Chemotherapie (HDIAC) von Lebermetastasen. Beitr.Onkol. 21 (1985) K. H. Link, Ch. Heidelberger, J. Landolph Induction of Quabain-resistant mutants by chemical carcinogens in rat prostate epithelial cells. Environmental Mutagenesis 5 (1983) Original papers coauthor Marko Kornmann, Karl-Heinrich Link & Andrea Formentini. Differences in colon and rectal cancer chemosensitivity. Colorect.Cancer 3(1), 1-13, 2014 Thomas Thomaidis, Annett Maderer, Andrea Formentini, Susanne Bauer, Mario Trautmann, Michael Schwarz, Wiebke Neumann, Jens Kittner, Arno Schad, Karl-Heinrich Link, Johannes Rey, Arndt Weinmann, Arthur Hoffman, Peter Galle, Marko Kornmann and Markus Moehler. Proteins of the VEGFR and EGFR pathway as predictive markers for adjuvant treatment in patients with stage II/III colorectal cancer: results of the FOGT-4 trial. Journal of Experimental & Clinical Cancer Research, 33:83 (02 Oct 2014) Marko Kornmann, Ludger Staib, Thomas Wiegel, Martina Kron, Doris Henne-Bruns, Karl-Heinrich Link, Andrea Formentini for the Study Group Ocology of Gastrointenstinal Tumors (FOGT). Long Term Results of 2 Adjuvant Trials Reveal Differences in Chemosensitivity and the Pattern of Metastases between Colon Cancer and Rectal Cancer. 21

22 Clinical Colorectal Cancer 12 (1), 54-61, 2013 Th. Weber, M. Roitman, K. H. Link. Peritonealkarzinose kolorektalen Ursprungs. Ergebnisse der Cytoreduktiven Chirurgie mit Peritonektomie und Hyperthermer Intraoperativer Chemotherapie. Chirurg 84, , 2013 E-pup (ahead of print ) DOI /s M. Kornmann, H. Hebart, K. Danenberg, R. Goeb, L. Staib, M. Kron, D. Henne-Bruns, P. Danenberg, K-H- Link. Response prediction in metastasized colorectal cancer using intratumoral thymidylate synthase Results of a randomized multicentre trial Eur J Cancer 48 (10) , 2012 (Epub 2011 Nov29) A. Formentini, P. Braun, H. Fricke, K-H. Link, D. Henne-Bruns, M. Kornmann. Expression of interleukin-4 and interleukin-13 and their receptors in colorectal cancer Int.J.Colorectal Dis.2012 Mar 24 [Epub ahead of print] Th. Weber, M. Roitman, K. H. Link. Current Status of Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy in Patients With Peritoneal Carcinomatosis From Colorectal Cancer. Clinical Colorectal Cancer 11 (3), , 2012 M. v. Knebel-Doeberitz et al. (u.a. K. H. Link, M. Kornmann) Br.J.Cancer 2012 M. Kornmann, L.Staib, T Wiegel, E-D Kreuser, M Kron, W Baumann, D. Henne-Bruns and K-H. Link. Adjuvant chemoradiotherapy of advanced resectable rectal cancer: results of a randomised trial comparing modulation of 5-fluorouracil with folinic acid or with interferon-a. 22

23 British Journal of Cancer 103, , 2010 W.Schmiegel et al. S3 Guidelines of Colorectal Carcinoma. Results of an Evidence-Based Consensus Conference on Colon- and Rectal Cancer. February 6/7, 2004 and June 8/ (for the Topics IV, VI and VII). (K. H. Link member of Work Group VI) Z Gastroenterolo 48, , 2010 Thomas Weber, Karl-Heinrich Link. Kolon: Pro Chirurgie. Hauptthema "Submukosakarzinome". Viszeralmedizin 25, 40-45, 2009 Hohenberger, W,, J. Spatz und M. Anthuber, U. Widmaier und M. H. Schoenberg. Stellenwert der laparoskopischen operativen Behandlung von Rektumkarzinomen. Chirurgische Praxis 70, 3-9, 2009 M. Kornmann, A. Formentini, C. Ette, D. Henne-Bruns, M. Kron, S. Sander, W. Baumann, E.-D. Kreuser, L. Staib,, Prognostic factors influencing the survival of patients with colon cancer receiving adjuvant 5-FU treatment. European Journal of Surgical Oncology (EJSO), Volume 34, , 2008 M. Kornmann, L. Staub, S. Sander, D. Henne-Bruns,. Prognostic factors influencing the outcome of 1652 patients with colon or rectal cancer receiving adjuvant 5-FU-based. European Journal of Surgical Oncology (EJSO), Volume 32, Suppl.I, 58-59, 2006 H. G. Beger, M. D. ; Bettina Rau, M. D.; PhD., Frank Gansauge, M. D., Bertram Poch M. D.,. Treatment of pancreatic cancer: challenge of the facts. 23

24 Wold J. Surg 27, , 2003 M. Kornmann, H.G. Beger,. Chemosensivity testing and test-directed chrmotherapy in human pancreatic cancer. Recent Results Cancer Res, 161, , 2003 B.U.M. Monz, H.-H. König, R. Leidl, L. Staib,. Cost Effectiveness of Adding Folinic Acid to Flourouracil Plus Levamisole as Adjuvant. Chemotherapy in Patients with Colon Cancer in Germany Pharmacoeconomics 21, , 2003 M. Kornmann, W. Schwabe, S. Sander, M. Kron, J. Sträter, S. Polat, E. Kettner, H. Weiser, W. Baumann, H. Schramm, P. Häusler, K. Otte, D. Beehnke, L. Staib, H. G. Beger, K-H. Link. Thymidylate synthase and dihydropyrimidine dehydropenase mrna expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil. Clinical Cancer Research, Vol 9, , M. Kornmann, H.G. Beger,. Chemosensivity testing and test-directed chrmotherapy in human pancreatic cancer. Recent Results Cancer Res, 161, , 2003 M. Kornmann,, I. Galuba, K. Ott, W. Schwabe, P. Häusler, P. Scholz, J. Sträter, S. Polat, B. Leibl, E. Kettner, Ch. Schlichting, W. Baumann, H. Schramm, U. Hecker, K. Ridwelski, J.H. Vogt, K.-U. Zerbian, F. Schütze, E.D. Kreuser, D. Behnke, H.G. Beger. Association of Time to Recurrence with Thymidylate Synthase and Dihydropyrimidine Dehydrogenase mrna Expression in Stage II and III Colorectal Cancer. The Society for Surgery of the Alimentary Tract, 6,3, , 2002 M. Kornmann, H.G. Beger,. Evaluation of toxicity using Oxaliplatin for regional intraarterial chemotherapy in patients with 24

25 colrorectal liver metastases. ICACT Abstract Book 11, S870, 2001 GH. Leder, B. Prokopcyk, M. Ramadani, AJ. Cunningham, M Siech, A. Schwarz, B. Poch, K.H. Link, M. Bologna, S. Amin. D. Desai, D. Hoffmann, K. El-Bayoumy, H.G. Beger Tobacco derived carcinogen in pancreatic juice of smokers - a causative factor for pancreatic cancer? Langenbecks Archives of Surgery, 386, 380, 2001 GH. Leder, B. Prokopcyk, M. Ramadani, AJ. Cunningham, M. Siech, A. Schwarz, B. Poch, K.H. Link, M. Bologna, S. Amin. D. Desai, D. Hoffmann, K. El-Bayoumy, H.G. Beger. Detection of tobacco derived carcinogen in pancreatic juice of smokers - a role for the onset of pancreatic cancer? Pancreas, 23, 448, 2001 GH. Leder, A. Formentini,, TH. Mattfeld, H.G. Beger. Successful reresections for pancreatic tumors. Langenbeck s Archives of Surgery, , 2001 JP Neoptolemos, DD Moffitt, JA Dunn, J. Almond, H.G. Beger,, P. Pederzoli, C. Bassi. Survival, quality of life and quality-adjusted survival of patients in the ESPAC-1 trial: An European randomzied trial to assess the roles of adjuvant chemotherapy and chemoradiation in resectable pancreatic cancer. Br. J. Surg 88/S1, 31, 2001 M. Kornmann,, S. Sander, M. Kron, J. Straeter, W. Schwabe, P. Haeusler, D. Behnke, H.G. Beger. Thymidylate synthase and dihydropyrimidine dehydrogenase expression in stage II and III colorectal cancer patients receiving adjuvant 5-fluorouracil. 25

26 Eur. J. Cancer 37, S300, 2001 M. Kornmann,, W. Schwabe, P. Haeusler, J. Straeter, S. Polat, P Danenberg, D. Behnke, H.G. Beger. MRNA quantitation of thymidylate synthase and dihydopyrimidine dehydrogenase can predict disease-free survival in stage IIb and III colon and stage II and III rectal cancer Gastroenterology S870, H.G Beger, M. Kornmann, Chemosensitivity testing and test-directed chemotherapy in pancreatic cancer Anti-Cancer Drugs 12, A13-A14, 2001 M. Kornmann, W. Schwabe, J Sträter, P. Häusler, H.G Beger,. Intratumoral thymidylate synthase levels can predict disease free survival in patients with colorectal cancer receiving adjuvant 5-FU chemotherapy. Deutsche Gesellschaft für Chirurgie Forumband 30, , 2001 J. P. Neoptolemos, J. A. Dunn, D. D. Stocken, J. Almond,, H. G. Beger, C. Bassi, M. Falconi, P. Pederzolli, C. Dervenis, L. Fernandesz-Cruz, F. Lacaine, A. Pap, D. Spooner, D. J. Kerr, H. Friess, M. W. Büchler for the members of the European Study Group on Pancreatic Cancer. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. The Lancet 358, , 2001 Ludger Staib,, H. G. Beger, and Members of the Forschungsgruppe Onkologie Gastrointestinaler Tumoren (FOGT). Toxicity and Effects of Adjuvant Therapy in Colon Cancer: Results of the German Prospective, Controlled Randomized Multicenter Trial FOGT- 1. Journal of Gastrointestinal Surgery, Vol.5, ,

27 M. Kornmann, W. Schwabe, J. Staeter, P. Haeusler, S. Polat, K. Danenberg, P. Danenberg, H.G. Beger, D. Behnke,. Thymidylate synthase quantitation predicts for disease-free survival in colorectal cancer patients receiving adjuvant 5-fluorouracil. American Association for Cancer Research, Annual Meeting, New Orleans, , Proc Am Assoc Cancer Res 42, 662, 2001 H.G Beger, M. Kornmann,. Chemosensitivity testing and test-directed chemotherapy in pancreatic cancer. Anti-Cancer Drugs 12, A13-A14, 2001 M. Kornmann, H.G. Beger,. Evaluation of toxicity using Oxaliplatin for regional intraarterial chemotherapy in patients with colrorectal liver metastases. ICACT Abstract Book 11, S870, 2001 GH. Leder, A. Formentini,, TH. Mattfeld, H.G Beger. Successful reresections for pancreatic tumors Langenbeck s Archives of Surgery, , 2001 JP Neoptolemos, DD Moffitt, JA Dunn, J. Almond, H.G. Beger,, P. Pederzoli, C. Bassi. Survival, quality of life and quality-adjusted survival of patients in the ESPAC-1 trial: An European randomized trial to assess the roles of adjuvant chemotherapy and chemoradiation in resectable pancreatic cancer. Br. J. Surg 88/S1, 31, 2001 J.Reusch, A.M. Keck,, H.H, Mohr. Koexistenz von zwei unterschiedlichen neuroendokrinen Tumoren des oberen Gastrointestinaltraktes und des Pankreas. Deutsche Medizinische Wochenschrift 123 (1998)

28 R.Mayer-Steinacker, Ch. Eggl,. Telefonische Beratungsstelle und Interdisziplinäres Onkologisches Konsil des Tumorzentrums Ulm - Wege zur Therapieoptimierung und Kostensenkung. Bericht über das 16. Jahrestreffen des Baden-Württembergischen Tumorzentrums, Onkologischen Schwerpunkte, Onkologischen Arbeitskreise und verwandten Organisationen (ATO), Ludwigsburg, Herausgeber: Krebsverband Baden-Württemberg e.v. (erschienen 1998) J.P.Neoptolemos, D.J. Kerr, H.G. Beger,, P. Pederzoli, C. Bassi, C. Dervenis, L. Fernandez-Cruz, F. Lacaine, H. Friess, M. Büchler. ESPAC-1 Trial Progress Report: The European Randomized Adjuvant Study Comparing Radiochemotherapy, 6 Months Chemotherapy and Combination Therapy versus Observation in Pancreatic Cancer. Digestion 58 (1997) M.Kornmann,, H-J. Lenz, J. Pillasch, R. Metzger, U. Butzer, et al.. Thymidylate synthase is a predictor for response and resistance in hepatic artery infusion chemotherapy. Cancer Letters 118 (1997) H.G.Beger, M.H. Schoenberg,, F. Safi, D. Berger. Die duodenumerhaltende Pankreaskopfresektion - Ein Standardverfahren bei chronischer Pankreatitis. Chirurg 68 (1997) F.Gansauge,, H.G. Beger. Adjuvante Therapie des Pankreaskarzinoms. Chir. Gastroenterol. 13 (1997) J.Goerich, N. Rilinger,, R. Sokiranski, T. Fleiter, V. Kunze, M. Siech, 28

29 A. Reiber, U. Leibing, M. Wikstroem, H.G. Beger, H.J. Brambs. Angiographic alteration of the hepatic arteries following transcatheter arterial liver embolization. Regional Cancer Treatment 9 ( ) J.Görich, N. Rilinger, R. Sokiranski, S. Krämer., H.G. Beger, H-J Brambs. Embolization of liver neoplams in patients with occluded celiac trunk. Reg Cancer Treat 9 (1996) F.Gansauge, S. Gansauge, N. Parker, M.I. Beger, B. Poch,, F. Safi, H.G. Beger. CAM A new diagnostic marker in pancreatic cancer. Br. J. Cancer 74 (1996) F.Gansauge,, N. Rilinger, R. Kunz, H.G. Beger. Adjuvante regionale Chemotherapie beim resezierten fortgeschrittenen Pankreascarcinom. Chirurg 67 (1996) F.Gansauge, S. Gansauge, Zobywalski A, Scharnweber C,, Nüssler A.K., H.G. Beger. Differential Expression of CD44 Splice Variants in Human Pancreatic Adenocarcinoma and in normal Pancreas. Cancer Res. 55 (1995) F.Gansauge,, N. Rilinger, R. Kunz, H.G. Beger. Regionale Chemotherapie beim fortgeschrittenen Pankreaskarzinom. Med.Klin. 90 (1995) J.Pillasch,, J. Görich, N. Rilinger, U. Widmaier, M. Weindel, H.J. Brambs, H.G. Beger. Intraarterial chemotherapy for nonresectable liver cancer: Effectivity and toxicity of hepatic interaarterial infusion, chemoembolization and the combination modality. Reg. Cancer Treat. 8 (1995)

30 R.Kunz,. Laparoskopische Leistenhernienreparation: Transperitoneal oder extraperitoneal? Chir. Gastroenterol. 111 (1995) F.Porzsolt, A. Wirth, R. Mayer-Steinacker, W. Voigt, B. Heymer,, M. Schulte, E.M. Röttinger. Qualitätssicherung in der Onkologie. Münch Med Wschr 136 (1994) P.Suhr,. Strahlentherapie beim Rektumkarzinom. Münch Med Wschr 136 (1994) H.G. Beger, F.W. Eigler, R. Engelhardt, G. Hartung, Ch. Herfarth, P. Hermanek, R. Herrmann, D.K. Hossfeld, Th. Junginger, R. Kirchner, E. Kreuser, U. Laffer,, H.J. Meyer, H. Pichlmaier, W. Queisser, H.R. Raab, R. Sauer, O. Scheibe, H.J. Schmoll, W. Stock, H. Wilke. Konsensus der CAO, AIO und ARO zur adjuvanten Therapie bei Kolon- und Rektumkarzinom vom Onkologie 17 (1994) F. Porzsolt, A. Wirth, R. Mayer-Steinacker, P. Suhr, N. Warszawski, M. Schulte, G. Negri, L. Kleeberger,, E. Betz, M.R. Sarkar, E. Röttinger. Quality Assurance in Oncology: Definition of Treatment Goal and Assessment of Its Achievement. Onkologie 17 (1994) F. Gansauge,, N. Rilinger, H.G. Beger. Regional chemotherapy in unresectable pancreatic cancer. Pancreas 9 (1994)

31 S. Gansauge, F. Gansauge,, B. Poch, M.H. Schoenberg, H.G. Beger. Detectable levels of autoantibodies directed against p53 in patients with pancreatic cancer. Eur.J.Surg.Oncol. 20 (1994) 314 F. Safi,, H.G. Beger. Is follow-up of colorectal cancer patients worthwile?. Dis. Colon Rectum 36 (1993) J.M. Friedrich, P. Schnarkowski,, K.A. Schumacher, S. Hoch. Flushable stent-system for internal drainage in occlusive jaundice. European Journal of Radiology 15 (1992) L. Staib,, M. Büchler. Steigerung der Zytotoxizität spezifischer monoklonaler Antikörper gegen humane Carzinomzellen durch GM-CSF in vitro. Onkologie 14 (1991) K.R. Aigner, H. Müller, H. Walther,. Drug filtration in high dose regional chemotherapy. Contributions to Oncology 29 (1988) K.R. Aigner, H. Walther,. Isolated liver perfusion with MMC/5-FU. Surgical technique, pharmacokinetics, clinical results. Contributions to Oncology 29 (1988) K. Schwemmle,, B. Rieck. Rationale and indications for perfusion in liver tumors: Current data. Worl J Surg 11 (1987)

32 H. Walther, K.R. Aigner,, H.J. Helling, K. Schwemmle. Reduktion des postoperativen Ödems nach der isolierten hyperthermen Extremitätenperfusion durch prophylaktische Anwendung von Aprotinin. Arzneimittelforschung/Drug Research 35 (1985) K.R. Aigner, H.J. Helling,, H. Walther, G. Bil. Zytostatikafiltration unter regionaler Chemotherapie. Beitr. Onkol. 21 (1985) K.R. Aigner, H. Walther, H.J. Helling,. Die isolierte Leberperfusion. Beitr. Onkol. 21 (1985) K.R. Aigner,, H.J. Helling, S. Stemmler. Intraarterielle Infusion, experimentelle Grundlagen - Klinik. Beitr. Onkol. 21 (1985) K.R. Aigner,, H. Walther. Hochdosierte regionale Chemotherapie bei Lebermetastasen. Beitr. Onkol. 21 (1985) K.R. Aigner, H. Walther, J.C. Tonn,, P. Schoch, K. Schwemmle. Die isolierte Leberperfusion bei fortgeschrittenen Metastasen kolorektaler Karzinome. Onkologie 7 (1984) K.R. Aigner,, K. Schwemmle. Die intermittierende arterielle Kurzinfusion zur lokalen Chemotherapie von Tumoren und Metastasen der Leber. Chirurg 55 (1984)

33 K.R. Aigner,, H. Walther. Isolated hepatic perfusion in advanced hepatic metastases from colorectal primary. Surgical Rounds 6 (1984) K.R. Aigner, A. Jungbluth,, H. Walther, H. Müller, K. Schwemmle, Th. Ringenberg, G. Börger, R. Ruppel, L. Illig, H. Voigt. Die isolierte hypertherme Extremitätenperfusion mit Vindesin, Dacarbazin und Cis-Platin bei der Behandlung Maligner Melanome. Onkologie 6 (1984) K.R. Aigner,, H. Woescher, W. Johannes, M. Hundeiker. Regional perfusion of VX 2 carcinoma with cis-ddp. Anticancer Research 3 (1983) K.R.Aigner, H. Walther,, K.H. Muhrer, R.D. Filler, K. Schwemmle, R. Seuffer, P. Schoch, C. Petreje, J.C. Tonn, H. Müller. Die intraarterielle Zytostatikainfusion bei Lebertumoren. Med.Klin. 78 (1983) K.H. Muhrer,. KCl carcinoma extracts as tumor antigens in the Electrophoretic Mobility Test: Clinical evaluation. Cancer Detection and Prevention 6 (1983) Y. Kubota, E.B. Gehly,, Ch Heidelberger. Development of two cloned epithelial cell lines from normal adult mouse and rat ventral prostates. In Vitro 17 (1981)

34 II. Book articles, Book editions, Published abstracts (p 34-57) - Book articles first author, J.Ritter. Inselzelltumoren und Zysten der Bauchspeicheldrüse - Diagnose und Chirurgische Therapie von Bauchspeicheldrüsentumoren bei VHL-Patienten. G.Alsmeier (VHL), P.H.Neumann (Ed.): Von Hippel-Lindau (VHL). Eine patientenorientierte Krankheitsbeschreibung. Books on Dermand, Norderstedt, 2010, 41-45, M. Hauser, M. Mann, P. M. Schlag. Kolonkarzinom Chirurgische Onkologie Strategien und Standards für die Praxis Michael Gnant, Peter M. Schlag (Hrsg.), Kapitel 23, Springer Wien/New York, 2008, J. Preiß. Prinzipien der lokoregionären Chemotherapie. in H.-J. Schmoll, K. Höffken, K. Possinger (Hrsg.): Kompendium Internistische Onkologie, 4. Auflage Standards in Diagnostik und Therapie Springer, , 2006, V. Apell, K. Tischbirek, M. Holtappels, K. Zayed, T.A. Sagban, M. Mörschel, T.F. Weigel, K.M. Josten, R. Thimm, L. Staib. Multimodality Treatment of Hepatic Metastases. In Focal Liver Lesions, Editors R. Lencioni, D. Cioni, C. Bartolozzi Springer, ,

35 . Chirurgisch-onkologische Therapie von Mammakarzinomlebermetastasen Management des Mammakarzinoms, R. Kreienberg, T.Volm, V. Möbus, D. Alt, Springer, 2. Auflage, 2002, K.H.Link. Chirurgisch-onkologische Therapie von Mammakarzinom-Lebermetastasen. In: R. Kreienberg (Hrsg): Management des Mammakarzinoms. Ein Leitfaden für die Praxis. Springer, Heidelberg (1998) , L. Staib, H.G. Beger. Adjuvante Therapie bei soliden Tumoren des unteren Gastrointestinaltraktes. In: H.G. Beger, A. Schwarz, U. Brückner, W. Hartel (Hrsg): Forschung in der Chirurgie. Springer, Heidelberg (1997) , F. Gansauge, J. Pillasch, M. Büchler, H.G. Beger. Regional Treatment of Advanced Pancreatic Carcinoma via Celiac Axis Infusion. In: H.G. Beger, M. Büchler, M.H. Schoenberg (Eds) Cancer of Pancreas, Universitätsverlag Ulm (1996) , E.D. Kreuser, F. Safi, A. Schalhorn, E. Schmoll, J. Pillasch, H.G. Beger. 5-FU+Folinic Acid (FA, Rescuvolin) i.a., 5-FU+FA i.v., 5-FUDR i.a., or 5-FUDR i.a.+ i.v. for treatment of nonresectable colorectal liver metaastases? In: P. Banzet, J.F. Holland, D. Khayat, M. Weil (Eds): Cancer Treatment. An Update. Springer, Paris (1994) , F. Safi, H.G. Beger. Ergebnisse der Tumornachsorge bei 1054 Patienten mit kolorektalen Karzinomen. Was bringt der Aufwand? in: Berichte über die Jahrestagung der ATO 11 35

36 (Krebsverband Baden-Württemberg) (1992) Basic concepts for the application of Mitomycin C in regional cancer treatment. In: T. Taguchi, K.R. Aigner (Eds.): Mitomycin C in Cancer Chemotherapy Today, Excerpta Medica, Tokyo (1991) 62-71, R. Kunz, J. Ullrich, H.G. Beger. Drug sensitivity testing for regional chemotherapy. In: P. Banzet, J.F. Holland, D. Khayat, M. Weil (Eds): Neo-Adjuvant Chemotherapy. Springer, Berlin (1991) Chemosensitvity-directed regional chemotherapy of liver metastases. In: H.G. Beger et.al. (Eds.): Cancer Therapy. Springer, Berlin (1989) Drug testing in regional chemotherapy of liver metastases. In: J. Kreidler,, K.R. Aigner (Eds): Advances in Regional Chemotherapy. Karger, Basel (1988) 79-91, W. Kühn, K.R. Aigner. In vitro bioassay for testing perfusate toxicity in isolation perfusion of extremity melanoma. In: S. Salmon (Ed): Adjuvant therapy of cancer. Grune & Stratton, Orlando (1987) K.H.Link. Chemosensitivitätstestung von Mitoxantron zur Eignung in der hochdosierten regionalen Kurzzeittherapie. In: S. Seeber., K.R. Aigner, E. Enghofer (Eds): Die Lokoregionale Tumortherapie. 36

37 De Gruyter, Berlin (1987) 13-19, K.R. Aigner, K.H. Schultheis, W. Kühn, H. Walther, K. Schwemmle. In-Vitro Sensitivitätstestung von Cytostatika bei regionaler Chemotherapie von (Melanom-) Lebermetastasen. In: H. Voigt und U.R. Kleeberg: Malignes Melanom Springer, Berlin (1986) , K.R. Aigner, K.H. Schultheis, W. Kühn, H. Walther, K. Schwemmle. High dose regional chemotherapy in melanoma liver metastases. Prediction of response in vitro. Proceedings of the 1st. International Conference On Skin Melanoma, Venice (1985) , J. Dobroschke, K.H. Sommerlad, H. Mueller. Abdominal Surgery in Patients on Chronic Hemodialysis. In FW Eigler and HD Jakubowski (eds.): Surgery in Chronic Renal Failure. Thieme, Stuttgart - New York, (1983) , K.R. Aigner, P. Hild, K. Henneking. The isolated extremity perfusion in melanomas and soft tissue sarcomas with Cis-Platinum, DTIC, and Vindesine. In: K.H. Spitzy and K. Karrer (Eds.): Proceedings of the 13th International Congress of Chemotherapy, Vienna (1983) 258/ Book articles coauthor Th. Weber und. Was gibt es Neues bei Mindestmengenvereinbarungen? In: Meßmer, Jähne, Neuhaus Eds: Was gibt es Neues in der Chirurgie, Jahresband 2011, ecomed,

38 A. Schalhorn,, W. Voigt. Regionale Chemotherapie von Lebermetastasen In: H.-J. Schmoll, K. Höffken, K. Possinger (Hrsg.). Kompendium Internistische Onkologie, 4. Auflage Standards in Diagnostik und Therapie. Springer, , 2006 M. Schulte,, L. Sunder-Plassmann. Operative Therapie bei (Mammakarzinom) Metastasen In (R. Kreienberg, T. Volm, V. Möbus, D. Alt, (Eds)): Management des Mammakarzinoms, 2. Auflage, Springer, Heidelberg 2002, F. Gansauge,, A. Formentini, M. Schatz, R. Röttinger, J. Görich, H.G. Beger. Adjuvant intra-arterial chemotherapiy with and without radiation therapy in pancreatic cancer Pancreatic Cancer, in: D. B. Evans, P. W. T. Pisters, J. L. Abruzzese (Editors): Pancreatic Cancer, Springer, New York, 2001; Paula Ghaneh, David Smith, Jennifer Almond, Deborah Moffitt, Janet Dunn, John Slavin, Robert Sutton, Claudio Passi, Paolo Pederzoli, Hans G. Beger, K. H. Link, Helmut Freiss, Markus Büchler, John P. Neoptolemos. European adjuvant trials in pancreatic cancer. In: D. B. Evans, P. W. T. Pisters, J. L. Abruzzese (Editors): Pancreatic Cancer, Springer, New York, 2001, M. Schulte,, L. Sunder-Plassmann. Operative Therapie des Mammakarzinoms bei Metastasen. In: R. Kreienberg, V. Möbus, D. Alt (Hrsg): Management des Mammakarzinoms. Springer, Heidelberg (1998) R.W.Dahlbender, C. Grünwald, G. Allert, D. Pokorny,, H. Kächele. Zum Beziehungs- und Interaktionsangebot des Liaisonpsychotherapeuten in einem chirurgisch- 38

39 onkologischen Team. In: R. Battegay, A.M. Däumling et al. (Eds): Gruppenpsychotherapie und Gruppendynamik, Vandenhoeck & Ruprecht, Göttingen, Zürich 32 (1996) H.G. Beger,, B. Poch. Therapie der chronischen Pankreatitis. In: Boeckl, Waclawiczek (Hrsg.): Standards in der Chirurgie. W. Zuckschwerdt-Verlag München (1995) H.G. Beger,, B. Poch, F. Gansauge. Pancreatic cancer - recent progress in diagnosis and treatment. In: Neoptolemos J.P., Lemoine N.R. (Eds.): Pancreatic Cancer. Molecular and Clinical Advances. Blackwell Science Oxford (1995) R.Schönmayr, J.C. Tonn,, H.P. Krämer. Chemosensitivity of malignant human brain tumors In vitro. In: J. Kreidler,, K.R. Aigner (Eds): Advances in Regional Cancer Therapy. Karger, Basel (1988) K.R. Aigner,, H. Walther. Chirurgische Therapie des malignen Melanoms. In: H. Voigt und U.R. Kleeberg (Eds.) Malignes Melanom. Springer, Berlin (1986) K.R. Aigner, H. Walther,. Perfusionstherapie (beim malignen Melanom). In: H. Voigt und U.R. Kleeberg (Eds.): Malignes Melanom. Springer, Berlin (1986) M. Schartl, R.U. Peter,, G. Klaus, Ch. Gisa. Behaviour of fish melanomas after transplantation onto nude mice. 39

40 Proc. 1.Int. Conf. on Skin Melanoma, Venedig (1985) H. Walther, K.R. Aigner,, HJ Helling, K. Schwemmle. Prevention of edema in isolated hyperthermic perfusion of the extremities. Proc. 1. Int.Conf. on Skin Melanoma, Venedig (1985) K.R. Aigner, H. Walther,, K.H. Muhrer, K. Schwemmle. Isolation perfusion of the liver as part of a multimodal therapeutic concept for liver metastasis. In: H.O. Klein: Advances in the Chemotherapy of Gastrointestinal Cancer. Perimed, Erlangen (1984) K.H. Muhrer, C. Johnsen,, K.R. Aigner. Carcinoembryonic antigen (CEA) and tissue polypeptide antigen (TPA) for therapy control after intraarterial chemotherapy of liver metastases. In: H.O. Klein: Advances in the Chemotherapy of Gastrointestinal Cancer, Perimed, Erlangen (1984) P. Schoch, K.R. Aigner, F. Schumacher, Z. Akengin,, S. Bayindir. Volumetry of liver metastases in cat-scan before and after regional liver perfusion and infusion. In: K.H. Spitzy, H.Karrer (Eds.): Proceedings of the 13th International Congress of Chemotherapy, Wien (1983) 282/1-3 - Books Editor/Coeditor etc., P. Heeckt, D. Klein, M. Schatz (Eds) Ernährung und Krebs. Fabri-Verlag, Ulm (2000)., D. Klein, P. Heeckt (Eds): Ernährung und Krebs. Oncological Seminar, Ulm Cancer center. CD-Rom,

41 H.G. Beger, (Eds) Gastroenterological Carcinogenesis. Monduzzi, Proceedings of the 8th International Conference of Regional Cancer Treatment. Regional Therapy of Cancer - The Future. Regional Cancer Treatment, Supplement I, (1997) K.R. Aigner, Y. Patt,, J. Kreidler Regional Cancer Treatment. Karger, Basel (1988). J. Kreidler,, K.R. Aigner. Advances in Regional Cancer Therapy. Proceedings of the III. International Conference on Advances in Regional Cancer Therapy (ICRCT 87), Karger, Basel (1988). -Abstracts (Published abstracts for congress presentations) -First author, W. Weidner, J. Kracht, C.F. Rothauge. Immunhistologische CEA-Darstellung in Blasentumoren - Erste Ergebnisse. Tagungsbericht der 26. Tagung der Nordrhein-Westfälischen Gesellschaft für Urologie (1980) 62, K.R. Aigner, H. Müller, K. Schwemmle. DTIC, Vindesine, and Cis-DDP in isolated extremity perfusion. Cancer Research and Clinical Oncology 107 (1984) 61, K.R. Aigner, H. Müller, K. Schwemmle. 41

42 DTIC, Vindesine, and Cis-DDP in isolated extremity perfusion. Verh. Dtsch. Krebs. Ges. 5, G. Fischer, Stuttgart (1984) 138, K.R. Aigner, W. Kuehn, K. Schwemmle. Wachstumshemmung colorektaler Lebermetastasen in vitro nach interoperativer hochdosierter regionaler Chemotherapie. Aktuelle Onkologie 28, Zuckschwerdt, München (1985) 248,, K.R. Aigner, W. Kühn, K. Schwemmle, K.H. Schultheis. Perioperative response determination in vitro in regional chemotherapy of colorectal liver metastases. Proceedings of ECCO 3, Stockholm (1985) 208,, K.R. Aigner. Immediate response determination in vitro following drug exposition in vitro by regional chemotherapy. Journal of Cancer Research and Clinical Oncology, Suppl. to Vol. 111, (1986) 98, K.R. Aigner, K. Schwemmle. Drug Testing in Regional Chemotherapy. J Cancer Res Clin Oncol, Suppl. to 111, (1986) 97, K.R. Aigner, C. Peschau. Concentration-time-dependant toxicity of 5-FU, 5-FUR, and 5-FUDR in colorectal carcinoma cell line HT 29. J Cancer Res Clin Oncol, Suppl. to 111, (1986) 93 K.H.Link, D. Kessler, K.R. Aigner. Dose response of Mitoxantrone in cell lines and human solid tumor biopsies with first results in regional chemotherapy. 42

43 J Cancer Res Clin Oncol, Suppl. to 111, (1986) 93, K.R. Aigner, D.H. Kern, K.P. Ramming. Chemosensitivity testing in high-dose regional chemotherapy Proceedings of the 77th AACR Meeting, Los Angeles (1986) 416, Ch. Gisa, K.H. Muhrer, H.P. Fischer, M. Altmannsberger, A. Köhler. Immunoreactivity of colorectal carcinoma celline NMG 64/84 in the electropheresis mobility test. J Cancer Res Clin Oncol 113 (1987) 43, D Kessler, K.R. Aigner, K. Schultheis. Chemosensitivity profiles of human solid tumors to various drugs. J Cancer Res Clin Oncol 113 (1987)54, K. Peschau, N. Rötering. Influence of concentration and exposure time on toxicity in the dual action of 5-FU in HT29 colorectal carcinoma cells. J Cancer Res Clin Oncol 113 (1987) 54, H.G. Beger. Individual drug selection for regional chemotherapy by in vitro testing. J Cancer Res Clin Oncol 114, (1988) 179, C.H. Gisa, K.H. Muhrer, H.G. Beger. T-cell dependent screening system to detect colon carcinoma. J Cancer Res Clin Oncol 114, (1988) 22, R. Kunz, L. Staib, J. Sixt. Drug selection by sensitivity testing at the high concentrations in regional chemotherapy. European Surgical Research 22, S1/90, (1990) 60 43

44 , J.M. Friedrich, R. Kunz. Transcutaneously accessible endoprosthesis for transduodenal bile drainage in inoperable occlusive jaundice. European Surgical Research 22, S1/90, (1990) 22, R. Kunz, L. Staib, H.G. Beger. Drug exposure concentration and -time as determinants of toxicity. Cancer Research and Clinical Oncology, 116 (1990) 452, R. Kunz, G. Hepp. Intraperitoneal regional chemotherapy (IPRC) with mitoxantrone (NOV). Regional Cancer Treatment 4 (1991) 27 K.H.Link, R. Kunz, J. Ullrich, H.G. Beger. Chemosensitivity tests predict response to regional chemotherapy. European Journal of Cancer, Suppl 2 (1991) 205, G. Hepp, W. Böhm, H.G. Beger. Novantrone (NOV). Intraperitoneal application - basic concepts and clinical results. J Cancer Res Clin Oncol, 118 Suppl (1992) R169, J. Ullrich, A. Schalhorn, H.G. Beger. Hepatic artery infusion (HAI) with 5-Fluorouracil and folinic acid (FA) in colorectal liver metastases (CRLM) via ports. J Cancer Res Clin Oncol, 118 Suppl (1992) R7, D. Kindler, M. Hummel, M. Büchler. Dose response treatment studies with two pancreatic carcinoma cell lines in vitro. Digestion 52, (1992)

45 , J. Ullrich, R. Kunz, H.G. Beger. Die Wertigkeit der In-vitro-Sensitivitätstestung (IVS) von Zytostatika. Acta Chirurgica Austriaca (ACA) 98 (1992) Pharmacology in regional chemotherapy. A review. Regional Cancer Treatment Suppl.1, (1993) 35. Impact of chemosensitivity testing on regional chemotherapy. Regional Cancer Treatment Suppl.1, (1993) 36, E.D. Kreuser, F. Safi, J. Ullrich, J. Pillasch. Optimal fluoropyrimidine therapy of colorectal liver metastases. Regional Cancer Treatment Suppl.1, (1993) 36 K.H.Link. Possibilities and developments in regional chemotherapy of malignant liver tumors. A review. Regional Cancer Treatment Suppl.1, (1993) 36, J. Pillasch, F. Safi, F. Gansauge, H.G. Beger. Advantages of Regional Chemotherapy in malignant Liver Tumors. J Cancer Res Clin Oncol 120 (1994) 74, H.G. Beger. Rationales for Adjuvant Therapy in Carcinomas of the Colon and Rectum. J Cancer Res Clin Oncol 120 (1994)

46 Possibilities of Regional Chemotherapy in Extrahepatic Tumor Sites. J Cancer Res Clin Oncol 120 (1994) 148, K.R. Aigner, J. Pillasch, J. Ullrich, F. Gansauge and D.H Kern. A Prospective Decision-Aiding Trial Used to Select Individualized Treatment Regimens for Patients Undergoing Regional Chemotherapy. Proceedings of the AACR, 35 (1994) 205, L. Staib, J. Pillasch, F. Gansauge, U. Butzer, H.G. Beger. Concentration Response Behaviour of Human Solid Tumor Cells to Chemotherapeutic Drugs In Vitro. Proceedings of the AACR, 35 (1994) 433, J. Pillasch, M. Weindel, H.G. Beger. Hepatic arterial infusion therapy (HAI) for treatment of isolated nonresectable colorectal liver metastases (CRLM). Mitoxantrone (NOV), 5-FU+Folinic Acid (FA), Mitomycin C (MMC) as standard therapy?. Proceedings of the Sixth International Congress on Anti-Cancer Treatment, Paris (1996) 135. Adjuvant therapy in pancreatic cancer. Proceedings of the Sixth International Congress on Anti-Cancer Treatment, Paris (1996) 49, J. Pillasch, M. Weindel, U. Widmaier, F. Gansauge, H.G. Beger. Regional chemotherapy of nonresectable isolated colorectal liver metastases (CRLM): Mitoxantrone (NOV), 5-FU+folinic acid (FA), and Mitomycin C (MMC) versus 5-FU+FA. Proceedings of the American Association for Cancer Research 37 (1996) 170, J. Pillasch, M. Weindel, G. Leder, H.G. Beger. Mitoxantrone, 5-FU + Folinic Acid, Mitomycin C for regional Chemotherapy of malignant Liver Tumors. Proceedings of the 18th Society Meeting, Japanese Society for Research of Loco-Regional Cancer 46

47 Therapy, Hiroshima (1996) 28, J. Pillasch, H.G. Beger. Regionale Chemotherapie von Lebertumoren nach individueller Chemosensitivitätstestung. Abstractband, 22. Deutscher Krebskongreß Berlin, Omnimed-Verlag, Hamburg (1996) 119, J. Pillasch, M. Weindel, H.G. Beger. Intraarterielle Infusion (HAI) zur Behandlung isolierter nichtresektabler colorektaler Lebermetastasen (CRLM): Mitoxantrone (NOV), 5-FU+Folinsäure (FS), Mitomycin C (MMC) vs. 5-FU+FS. Langenbecks Arch. Chir., Suppl. I, Chirurgisches Forum (1996) 620. Standards/Studies. Regional or systemic treatment in liver metastatic tumors, FOGT 3- Study. Regional Cancer Treatment, Suppl. 1, (1997) 72. Standards and studies for advanced pancreatic cancer. Regional Cancer Treatment, Suppl. 1, (1997) 73, J. Pillasch, M. Weindel, G. Leder, H.G. Beger. Mitoxantrone, 5-FU + Folinic Acid, Mitomycin C for Regional Chemotherapy of Malignant Liver Tumors. Jap. J. Cancer and Chemotherapy 23 (1997) 1380, J. Pillasch, M. Weindel, A. Formentini, F. Safi, J. Limmer, H.G. Beger. Development of regional chemotherapy in nonresectable colorectal liver metastases. Rationale for a randomized trial. Proceedings - Seventh International Congress on Anti-Cancer Treatment, Paris (1997) 95, G. Leder, G. Hepp, H. Urbanczyk, H. Schmid. 47

48 Retrospective analysis of intraperitoneal instillative chemotherapy with Mitoxantrone in 143 patients with malignant ascites of breast and gynecological pelvic cancer: a safe and effective palliation. Regional Cancer Treatment, Suppl. 1, (1997) 45, L. Staib, H. Bernhart, E.D. Kreuser, P. Suhr, E. Röttinger, H.G. Beger. Interim report on toxicity compliance of the FOGT 1 and FOGT 2 trials for adjuvant postoperative therapy in colon- and rectal cancer. European Journal of Cancer, 33, Suppl 8, (1997) 342, L. Staib, H. Bernhart, E.D. Kreuser, P. Suhr, E. Röttinger, H.G. Beger for the Forschungsgruppe Onkologie Gastrointestinaler Tumoren (FOGT). Toxicity and compliance of the FOGT-1 and FOGT-2 trials for adjuvant postoperative therapy in colonand rectal cancer. An Interim Report. Proceedings 8th International Congress on Anti-Cancer Treatment, Paris (1998) 98, A. Formentini, G. Leder, H.G. Beger. Multimodal treatment concepts to improve survival in nonresectable and resectable pancreatic cancer. Proceedings 8th International Congress on Anti-Cancer Treatment, Paris (1998) 123, J. Pillasch, A. Formentini, E. Sunelaitis, G. Leder, F. Safi, E. Papachristou, H. Allmendinger, R. Dahlbender, H.G. Beger. Development of hepatic artery infusion (HAI) protocols in nonresectable isolated colorectal liver metastases (CRLM). Proceedings 8th International Congress on Anti-Cancer Treatment, Paris (1998) 105, G. Leder, J. Staib, J. Pillasch, F. Gansauge, M. Kornmann, A. Formentini, U. Butzer, H.G. Beger. Regional chemotherapy of nonresectable colorectal liver metastases and advanced pancreatic cancer - from basic science to phase II and III studies. 48

49 Annals of Cancer Research and Therapy 18 (1998) , L. Staib, E. Röttinger, H.G. Beger. Toxizität und Akzeptanz der adjuvanten Therapie von Kolon- und Rektumkarzinomen im Rahmen der interdisziplinären FOGT 1 und 2 Studien. In Ch. Herfarth und W. Hartel (Eds.) Kurzreferate 115. Kongress der Deutschen Gesellschaft für Chirurgie, Barth, Heidelberg (1998) 259, A. Formentini, J. Pillasch, H.G. Beger Die regionale Chemotherapie primär nichtresektabler kolorektaler Lebermetastasen kann eine sekundäre Resektabilität induzieren. In Ch. Herfarth und W. Hartel (Eds.) Kurzreferate 115. Kongress der Deutschen Gesellschaft für Chirurgie, Barth, Heidelberg (1998) 185, A. Formentini, G. Leder, G. Fortnagel, F. Gansauge, H.G. Beger. Achievements and developments of regional cancer chemotherapy in non-resectable and resected pancreatic cancer. European Journal of Surgical Oncology, 24 (1998) 210, M. Kornmann, G. Leder, K. Danenberg, P.V. Danenberg, H.G. Beger. Thymidylate synthase (TS) is a prognostic determinant in regional chemotherapy of colorectal liver metastases. European Journal of Surgical Oncology, 24 (1998) 218, J. Pillasch, A. Formentini, G. Leder, E. Sunelaitis, H. Allmendinger, E. Papachristou, H.G. Beger. Intraarterial infusion of malignant liver tumors via ports. Journal of Cancer Research and Clinical Oncology Suppl. Vol. 124 (1998) R15, J. Pillasch, G. Leder, A. Formentini, L. Staib, H.G. Beger. 49

50 Choice of therapy for liver metastases from colorectal cancer. Regional chemotherapy with the possibility of downstaging and secondary resection. The Journal of the Japan Society of Coloproctology, 51 9 (1998) P1-1. Adjuvant treatment of colon- and rectal cancers. Toxicity analysis of FOGT1- and FOGT 2 trials. Annals of Hematology Vol 77 (Suppl II) (1998) 106. Quality control in colon- and rectal cancer surgery BMC Proceedings 2010, 4/Suppl 2), O23 K-H. Link for the FOGT. Surgical oncology and translational research: Ideas, laboratory task, clinical results and merits. Book of abstracts, 18. Charles Heidelberger Symposium on Cancer Research "Translational Research from bench to Bedside", Ulm, Published abstracts coautor K.R. Aigner,, H. Walther, K. Schwemmle. Combined treatment of liver tumors: Isolated perfusion, resection, hepatic artery infusion. Cancer Research Clinical Oncology 107 (1984) 75 K.R. Aigner,, H. Walther, K. Schwemmle. Combined treatment of liver tumors: Isolated perfusion, resection, hepatic artery infusion. Verh.Dtsch. Krebs. Ges. 5, Gustav Fischer, Stuttgart (1984) 489 H. Walther, K.R. Aigner,, K. Schwemmle. 50

51 Intraarterial infusion chemotherapy with regional venous drug hemofiltration combined with surgery in treatment of two cases with malignant tumors. Cancer Research Clinical Oncology 107 (1984) 64 E.D. Kreuser,, F. Porzsolt, G. Steinmann, P.V. Danenberg. Heterogenous sensitivity of human colon cancer cell lines to 5-Fluorouracil, Folinic Acid, and Dipyridamole. Proceedings of the American Association of Cancer Research (AACR) 30 (1989) 571 E. Thiel, E.D. Kreuser, C. Garbe,, G Steinmann, P.V. Danenberg. A feasable fluorometric assay for determining interaction of cytokines and drugs in human cancer cell lines. Cancer Research and Clinical Oncology 116 (1990) 454 L. Staib, R. Kunz, G. Hepp,. Cyclic intraperitoneal chemotherapy with mitoxantrone (NOV). Cancer Research and Clinical Oncology 116 (1990) 692 J.M. Friedrich,, K.A. Schumacher. Port connected endoprosthesis for internal drainage. Radiology 177 (1990) 251 R. Kunz, L. Staib, J. Sixt,. Individual chemosensitivity testing at the high concentration range of regional chemotherapy. Cancer Research and Clinical Oncology, 116 (1990) 601 J.M. Friedrich,, K.A. Schumacher, T. Heuchemer, W. Weidenmaier. Flushable biliary stent: Long-term results. Radiology 181 (1991)

52 L. Staib,, M.S. Mitchell. Immunomodulation of pancreatic cancer in vitro. Effect of monoclonal antibodies, GM-CSF and lymphokine-activated killer cells. Digestion 52 (1992) 124 F. Gansauge,, M. Büchler, H.G. Beger. Split-Time resection of 'unresectable' colorectal liver metastases supported by chemosensitivity directed hepatic artery infusion. Regional Cancer Treatment Suppl 1 (1993) 25 S. Gansauge,, M. Hummel, D. Kindler, H.G. Beger. Establishment and In-Vitro Toxicity Studies of Two New Pancreatic Carcinoma Cell-Lines PMH2/89 and PMH3/89. J Cancer Res Clin Oncol 20 (1994) 311 F. Gansauge,, W. Schlosser, N. Rilinger, M. Büchler, H.G. Beger. Effectivity and Toxicity of Regional Chemotherapy in Pancreatic Carcinoma. Eur J Surg Oncol 20 (1994) 312 F. Gansauge,, J. Pillasch, M. Büchler, H.G. Beger. Regional Chemotherapy in Advanced Pancreatic Carcinoma. J Cancer Res Clin Oncol 20 (1994) 74 S. Gansauge, F. Gansauge,, M.H. Schoenberg, B. Poch, H.G. Beger. Prevention of liver metastases in pancreatic carcinoma by autoantibodies directed against p53. Int. J. Pancreatol. 16 (1994) 313 S. Gansauge, F. Gansauge,, M.H. Schoenberg, B. Poch, H.G. Beger. p53-autoantibodies in diseases of the pancreatico-biliary system. Pancreas 9 (1994)

53 J. Pillasch,, N. Rilinger, L. Staib, H.G. Beger. Regional Chemotherapy of Primary Hepatic Cancer - Effectivity and Toxicity. Eur J Surg Oncol 20 (1994) 321 F. Porzsolt, A. Wirth, R. Mayer-Steinacker, W. Voigt, B. Heymer,, M. Schulte, E. Röttinger. Quality Assurance in Palliative Treatment: Goals Should be Defined, Specified, and Monitored. ASCO Proceedings 13 (1994) 188 L. Staib, U. Butzer,, H.G. Beger. Immune Reactivity in Colorectal Cancer Patients. Eur J Surg Oncol 20 (1994) L. Staib, U. Butzer,, H.G. Beger. Immune Reactivity is Reduced in Patients with Advanced Colorectal Cancer. Proceedings of the AACR 35 (1994) 249 F. Safi, G. Hepp,, H.G. Beger. Simultaneous adjuvant regional and systemic chemotherapy after resection of liver metastases of colorectal cancer. Proceedings of ASCO (Abstract-Book) 14 (1995) 217 F. Gansauge,, N. Rilinger, T. Rehwagen, H.G. Beger. Regional Chemotherapy in unresectable Pancreatic Cancer. Proceedings of the Fifth International Congress on Anti-Cancer Chemotherapy. Paris (1995) 150 M. Weindel, J. Pillasch,, N. Rilinger, Ch. Schaller, H.G. Beger. Regional i.a. chemotherapy of colorectal liver metastases: Effectivity and toxicity of a new drug combination. 53

54 Proceedings of the Fifth International Congress on Anti-Cancer Chemotherapy. Paris (1995) 242 A. Formentini,, G. Fortnagel, J. Pillasch, H.G. Beger. Hepatic artery infusion for chemotherapy of primary and metastatic liver tumors via a port catheter system: a safe and feasible procedure. Regional Cancer Treatment, Suppl. I, (1997) 12 A. Formentini,, J. Pillasch, H.G. Beger. Neoadjuvant regional chemotherapy for non resectable pancreatic and hepatic tumors. Regional Cancer Treatment, Suppl. I, (1997) 60 L. Staib, H. Braunmüller,, H.G. Beger. Immune reactivity of regional lymph nodes in human pancreatic cancer is decreased compared to blood cells. Proceedings of the American Association of Cancer Research (AACR) 38 (1997), 121 A. Formentini,, J. Pillasch, H.G. Beger A seven years experience with implantable devices for regional hepatic arterial chemotherapy: usability time, incidence and management of complications. European Journal of Cancer, 33, Suppl 8 (1997) 164 J.Görich, N. Rilinger, R. Sokiranksi, S. Krämer, A. Aschoff,, H.J. Brambs. Intraarterial chemotherapy in recurrent breast cancer. Journal of Cancer Research and Clinical Oncology Suppl. Vol. 124 (1998), R15 N. Warszawski,, A. Warszawski, B.M. Schneider, E.M. Röttinger. Treatment factors influencing survival in pancreatic carcinoma. Journal of Radiation Oncology, Biology, Physics 174 Suppl 1 (1998) 103 F. Gansauge,, C. Rehwagen, H.G. Beger. 54

55 Regionale Chemotherapie bei nicht-resezierbarem und palliativ reseziertem Pankreaskarzinom. Lang.Arch.Chir.Suppl. II (1995) 598 L. Staib,, H.G Beger. Morbidität und Langzeitüberleben nach Resektion uni- und multizentrischer kolorektaler Karzinome Dt. Gesellschaft Chirurgie (Kongressband 2001), 835, 2001 L. Staib, KH Link, HD Harzer, A. Käsbohrer, V. Liebig, H.G Beger. Adjuvante Therapie des Kolonkarzinoms mit 5-FU/Folinsäure/Levamisol: Überlegenheit in der Kosten-Nutzen Analyse der Mulicenterstudie FOGT-1 Dt. Gesellschaft Chirurgie (Kongressband 2001), 84, 2001 L. Staib,, H.G Beger. Morbidität und Langzeitüberleben nach Resektion uni- und multizentrischer kolorektaler Karzinome Dt. Gesellschaft Chirurgie (Kongressband 2001), 835, 2001 M. Kornmann, W. Schwabe, J. Staeter, P. Haeusler, S. Polat, K. Danenberg, P. Danenberg, H.G Beger, D. Behnke,. Thymidylate synthase quantitation predicts for disease-free survival in colorectal cancer patients receiving adjuvant 5-fluorouracil American Association for Cancer Research, Annual Meeting, New Orleans, , Proc Am Assoc Cancer Res 42, 662, 2001 M. Kornmann,, S. Sander, M. Kron, J. Straeter, W. Schwabe, P. Haeusler, D. Behnke, H.G. Beger. Thymidylate synthase and dihydropyrimidine dehydrogenase expression in stage II and III colorectal cancer patients receiving adjuvant 5-fluorouracil Eur. J. Cancer 37, S300,

56 M. Kornmann,, W. Schwabe, P. Haeusler, J. Straeter, S. Polat, P Danenberg, D. Behnke, H.G. Beger. MRNA quantitation of thymidylate synthase and dihydopyrimidine dehydrogenase can predict disease-free survival in stage II b and III colon and stage II and III rectal cancer Gastroenterology S870, 2001 M.Kornmann, L.Staib, S.Sander, D.Henne-Bruns, and. Prognostic factors influencing the outcome of patients with colorectal cancer receiving adjuvant 5-FU based chemotherapy. AACR Meeting Abstracts Vol.49, A 4459, 2008 Sabine Grösch, Ruth Wanger, Sina Fuchs, Nerea Ferreiros, Gerd Geisslinger, Anna Höh, Anette Fisseler-Eckhoff, Karl-Heinrich Link. The role of ceramides in colon cancer. Book of abstracts, 18. Charles Heidelberger Symposium on Cancer Research "Translational Research from bench to Bedside", Ulm, 2012 L. Staib, T. Renz, F. Schuilcher, B. Hübner, K. Schüle, M. Geissler, H. Gnann, M. Kornmann,. Neoadjuvant rediochemotherapy in advanced rectal cancer - a single institution experience. Book of abstracts, 18. Charles Heidelberger Symposium on Cancer Research "Translational Research from bench to Bedside", Ulm, 2012 L. Staib, M. Kornmann, D. Henne-Bruns,. How accurate is preoperative local staging in resectable rectal cancer? Book of abstracts, 18. Charles Heidelberger Symposium on Cancer Research "Translational Research from bench to Bedside", Ulm, 2012 Casuistics/Case reports 56

57 und J. Kracht. Malakoplakie der Urethra - Eine außergewöhnliche Lokalisation. Pathologe 2, , 1981 W. Weidner, R. Pust, J. Kracht,. Sekundäre Harnleiterobstruktion bei metastasierendem Magenkarzinom - Eine Kasuistik. Verhandlungsbericht der Deutschen Gesellschaft für Urologie, 34. Tagung, , 1982, P. Hild,. Maligne entartetes Steißbeinteratom beim Erwachsenen. Chirurg 53, , 1982 III Oral Presentations (p ) Oral Presentations First author K.H.Link Colon- and rectal Cancer Multimodal Therapy: How to avoid and treat complications 10 th International Interdisciplinary Colon and Rectal Cancer Conference Tongji University School of Medicine and Shanghai Municipal Center for Disease control and Prevention, Shanghai, November 14 th,

58 K.H.Link Multimodale Behandlung/Chirurgie des Pankreaskarzinoms. Ergebnisse an der APK Wiesbaden mit Benchmarking national/international. Weiterbildungsseminar CHZ, APK Wiesbaden 10/2015 K.H.Link Chirurgische Onkologie in der Allgemein- und Viszeralchirurgie. Behandlung von Primärtumoren und Metastasen. Fortbildungsseminar für Internistische Onkologen (SIO) Berlin, 10/2015 K.H.Link Onkologisches Zentrum APK Wiesbaden. Strukturen - Vernetzungen APK, Wiesbaden Kolon- und Rektumkarzinom - Qualität in der Behandlung: Benchmarking der Ergebnisse des DZ APK Wiesbaden Fortbildung des CHZ APK,

59 Enddarmerkrankungen - Behandlungsmöglichkeiten: Polypen und Karzinome Medizin Bürgernah, Asklepios Paulinen Klinik, Wiesbaden, "1000 Mutige Männer für Wiesbaden" (1000 MM WI). Abschlussergebnisse der Aktion. DGIM Patiententag, Rathaus Wiesbaden, "1000 Mutige Männer für Wiesbaden" (1000 MM WI). Zwischenergebnisse der Aktion.Schloss Biebrich, Wiesbaden, (Weltkrebstag), M. Roitman, Th. Weber + Team Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC) in peritoneal metastasis from colon- and rectal cancer. Surgical Center and Asklepios Tumor Center (ATC), Asklepios Hospital APK, Wiesbaden, Germany ISSO Meeting, Caesarea,

60 , M. Kornmann, L. Staib, M. Roitman, Th. Weber, J. Kneip, and M. Schatz Colon- and Rectal Cancer. Developments up to date and future. ISSO Meeting. Caesarea, "1000 Mutige Männer für Wiesbaden"(1000 MM WI). Zwischenergebnisse der Aktion. MCS Eltville , M. Kornmann, L. Staib, M. Roitman, Th. Weber, and M. Schatz for Ulm University - German Study Group FOGT (K.H.L., M.K., L.St., M.Sch.) and Surgical Center and Asklepios Tumor Center (ATC) 60

61 Asklepios Paulinen Klinik (APK), Wiesbaden, Germany (K.H.L., M.R., Th.W.). Colon- and Rectal Cancer: Developments up to date and future. USC /Norris Comprehensive Cancer Center, Los Angeles, USA, Welche Chirurgen und Teams haben die besten Operationsergebnisse? Qualität in der Krebsbehandlung, Patientenseminar, APK, Prevention Campaign against Colon and Rectal Cancer: "1000 MM WI". ICRCC Meeting, Ulm,

62 Chirurgische Behandlung von gut- und bösartigen Pankreastumoren: Qualitätsansprüche und Ergebnisse Bauchspeicheldrüsenentzündungen und Tumore, APK, , M. Kornmann, L. Staib, M. Roitman, Th. Weber, M. Schatz, S. Peth, and J. Kneip Review lecture: Colon and rectal cancer: Developments up to date and Future, Southeast Chinese Surgical Meeting, Nanjing, July 6th, 2013, M. Roitman, Th. Weber + Team Chirurgie der Peritonealkarzinose und hypertherme intraperitoneale Chemotherapie 62